Related Experiment Video
Updated: Jan 10, 2026

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
Adjuvant Immunotherapy in Lung Cancer: Foundational Successes and Future Directions
Juliann E Kosovec1, Kaitlin C Bevers1
1Division of Cardiovascular and Thoracic Surgery, Duke University Medical Center, Box 3531 Med Ctr, Durham, NC 27710, USA.
Abstract:
This comprehensive article explores the adjuvant use of immunotherapy in resectable lung cancer, specifically highlighting the impact of foundational trials including IMpower010 and KEYNOTE-091. These studies were the first to demonstrate improved survival with perioperative immunotherapy, particularly in programmed death-ligand 1-positive patients. The article also examines the potential of adjuvant immunotherapeutics across non-small cell lung cancer subtypes and in small cell lung cancer. Emerging therapies are discussed, emphasizing the importance of biomarker-driven approaches. Future opportunities for therapeutic development may focus on optimization of patient-specific perioperative strategies through molecular subtyping and combined therapies.
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

